Notice of Extra General Meeting

Shareholders in ChronTech Pharma AB (publ) are hereby summoned to an Extra
General Meeting (EGM) Thursday the 16th of May 2013, at 14.00 at Kilpatrick
Townsend Lawfirm’s office, Hovslagargatan 5 B, 5 tr in Stockholm.

Application

To participate in the EGM shareholders shall both be incorporated in the of
Euroclear Sweden AB kept book of shareholders on the 10th of May 2013, and apply
for participation at the EGM to the Company via mail at the address ChronTech
Pharma AB, Hälsovägen 7, 141 57 Huddinge, per fax 08-449 84 81, per telephone 08
-449 84 80, per e-post asa.ekstrand@chrontech.se, or via the Company’s home page
www.chrontech.se. Application must have been received at the latest by Friday,
the 10th of May 2013. Shareholders who have their shares registered with a
trustee must in good time before the 10th of May 2013 have their shares
temporarily have their shares registered in their own name in order to
participate in the EGM.

Suggested Agenda

1.                        Opening of the EGM

2.                        Election of chairman for the EGM

3.                        Establishment and approval of shares for voting

4.                        Approval of the Agenda

5.                        Election of one or two Protocol Adjusters

6.                        Inquiry of whether the EGM has been duly been summoned

7.                        Proposal for the sale of the Company’s hepatitis
technologies

8.                        Closing of the EGM

Proposal for reconstruction of the Company (item 7)

The Board of Directors of ChronTech Pharma AB (”the Company”) put forward the
following additional proposal as step in the reconstruction of the Company as a
complement to what was decided at the EGM of the 19th of April 2013. The group
of shareholders has now offered to acquire the entire, i.e. also the remainder
30% and not only approximately 70% of the Company’s project regarding
development of DNA vaccines against hepatitis B and hepatitis C. The purchase
consideration now also includes a deferred consideration of 1 MUSD. The proposal
also includes the funding of the development of the IVIN DEVICE for use in
combination with hepatitis vaccines up to US$1,500,000 on the development of the
IVIN DEVICE in exchange for an exclusive license for use with hepatitis
vaccines. Please see attached “term sheet”.

Shareholders representing more than 60 per cent of the shares in the Company
have declared that they support the proposal for reconstruction.

Others

The complete proposal for decision will be held accessible at the Company
(address and telephone number as above) and on the Company’s home page
www.chrontech.se and will be sent to those shareholders who apply for this with
the Company.

Huddinge in April 2013

CHRONTECH PHARMA AB (publ)

The Board

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@chrontech.se

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs
against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic
infections with jaundice causing viruses which can lead to liver cirrhosis and
liver cancer. ChronTech has also developed and further develops a patent pending
new type of injection needle for a more effective uptake of DNA vaccines.
ChronTech also have part ownership in the wound healing therapy ChronSeal®, and
in the new platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium Nordic AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.